Fukuda Denshi (6960) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
31 Jul, 2026Executive summary
Revenue for Q1 FY2027 was ¥30,985 million, up 2.0% year-over-year, with operating profit at ¥4,592 million, up 9.9%, and net profit attributable to shareholders at ¥3,079 million, up 8.8%.
The business environment remains uncertain due to global geopolitical risks, but the domestic economy is on a moderate recovery path.
Medical industry trends include digital transformation and regional healthcare collaboration.
Financial highlights
Gross profit for Q1 FY2027 was ¥16,814 million, with a gross margin of 54.3%.
Operating profit margin improved to 14.8% from 13.8% year-over-year.
Comprehensive income surged to ¥6,920 million, up 115.7% year-over-year.
EPS for Q1 FY2027 was ¥113.97, up from ¥100.87 in the prior year.
Outlook and guidance
Full-year FY2027 revenue forecast is ¥142,000 million (+1.6% YoY), with operating profit of ¥25,500 million (–4.2%), and net profit of ¥17,700 million (–5.8%).
No change to previously announced full-year guidance; Q1 results were in line with expectations.
The company notes that Q4 is typically the peak sales period.
Latest events from Fukuda Denshi
- Modest sales and profit growth, with FY2027 guidance signaling lower earnings and a compliance incident.6960
Q4 2026 - Slight YoY profit decline offset by strong comprehensive income and stable full-year outlook.6960
Q3 2026 - Net sales up 0.8% and operating profit steady, with segment shifts and stable full-year outlook.6960
Q2 2026 - Sales rose 4% year-over-year, but profits declined; full-year guidance and dividends unchanged.6960
Q1 2025 - First-half profits fell on lower sales, but full-year guidance and dividend plans remain unchanged.6960
Q2 2025 - Profits declined despite stable sales, with mixed segment performance and steady full-year outlook.6960
Q3 2025 - Slight declines in sales and profit, with FY2026 guidance indicating further contraction.6960
Q4 2025 - Profits declined despite stable sales; medical treatment and consumables segments showed growth.6960
Q1 2026